ArticleMacromolecular rapid communications2026
A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform.
Article in Macromolecular rapid communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polyethylene glycol (PEG) plays a central role in nanomedicine, providing essential properties such as the stealth effect. However, the emergence of anti-PEG antibodies (APAs) increasingly undermines these benefits, raising concerns about safety and efficiency. This creates an urgent need for PEG alternatives. Randomized PEG (rPEG) represents a conceptually new strategy that preserves the PEG-like structure and performance while markedly reducing antigenicity. In this work, rPEG is employed as a non-antigenic A-block in ABA-type polymeric micelles (PMs). To enhance drug loading capacity beyond conventional PMs, the hydrophobic middle block is composed of poly(2-phenyl-2-oxazine) (PPheOzi). rPEG is synthesized by anionic ring-opening polymerization, PPheOzi by cationic ring-opening polymerization, and the combined rPEG-b-PPheOzi-b-rPEG triblock copolymers are linked via copper-catalyzed azide-alkyne cycloaddition. The formulations exhibit a distinct correlation between the solubilization of Efavirenz and the systematically varied rPEG composition, ranging from outstanding to moderate micelle drug loading capacities. A fundamental preclinical safety profile was established through investigations in murine fibroblasts and human peripheral blood mononuclear cells (PBMCs). Competitive enzyme-linked immunosorbent assays (ELISA) revealed a pronounced reduction in APA affinity in comparison to PEG. Taken together, the synergistic combination of rPEG and PPheOzi establishes a non-antigenic micellar platform capable of achieving high drug loadings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.